에서 실시간으로 운영 중이에요! 자세히 알아보기
66.18 USD
-0.40
0.6%
장 마감 시점 업데이트됨 10월 16일 PM 4:00 EDT
프리마켓
시간외 거래
66.28
+0.10
0.15%
1일
-0.6%
5일
2.96%
1개월
-0.18%
3개월
-6.29%
6개월
-16.81%
연초 이후
-14.72%
1년
-12.23%
5년
-15.46%
10년
14.02%
 

소개: Alcon is one of the leading visioncare companies in the world. Following nine years as a Novartis subsidiary, it was spun off as a public company in April 2019. Alcon operates in two segments: visioncare and surgical. Visioncare comprises contact lenses, lenscare solutions, and a suite of ocular health products. With brands like Dailies, Total1, and Air Optix, Alcon controls about one fourth of the US contact lens market. Surgical comprises intraocular lenses, ophthalmic surgical equipment, and consumables used during surgeries. Its main products include Centurion, a phacoemulsification device used during cataract surgeries, and a portfolio of IOLs including PanOptix and Vivity. Alcon has one of the largest installed bases of eye surgical equipment in the world.

직원 수: 25,942

뉴스

긍정적
중립
부정적
투자 심리 3개월
긍정적 52.6%
중립 36.8%
부정적 10.5%
중립
Business Wire
14시간 전
FDA Approves Alcon's BRYTLY Redness Reliever Eye Drops for Up to 12 Hours of Whiter, Brighter-Looking Eyes
GENEVA--(BUSINESS WIRE)--FDA Approves Alcon's BRYTLY Redness Reliever Eye Drops for Up to 12 Hours of Whiter, Brighter-Looking Eyes.
FDA Approves Alcon's BRYTLY Redness Reliever Eye Drops for Up to 12 Hours of Whiter, Brighter-Looking Eyes
부정적
Zacks Investment Research
지난달
Is it a Prudent Move to Retain ALC Stock in Your Portfolio Now?
Alcon's acquisitions, partnerships and new product launches support growth, but tariffs and intense competition remain key risks.
Is it a Prudent Move to Retain ALC Stock in Your Portfolio Now?
긍정적
Seeking Alpha
지난달
Alcon: A Re-Rating In Eyesight
Alcon is a structurally advantaged ophthalmology leader with a durable equipment-to-consumables model and strong recurring revenue streams. At $72, ALC trades at ~18x forward earnings, reflecting mid-teens EPS growth but pricing in neither margin expansion nor pipeline optionality. Management targets 25% core operating margin by FY2027E, with current core EPS guidance raised to +12–15% growth and significant capital returns underway.
Alcon: A Re-Rating In Eyesight
중립
Business Wire
지난달
Alcon Launches UNITY M, a Premium Ophthalmic Microscope Delivering Precise Control
GENEVA--(BUSINESS WIRE)--Alcon Launches UNITY® M, a Premium Ophthalmic Microscope Delivering Precise Control.
Alcon Launches UNITY M, a Premium Ophthalmic Microscope Delivering Precise Control
중립
Business Wire
지난달
Alcon Prices EUR 500 Million Senior Notes Offering
GENEVA--(BUSINESS WIRE)--Alcon Prices EUR 500 Million Senior Notes Offering.
Alcon Prices EUR 500 Million Senior Notes Offering
긍정적
Seeking Alpha
2개월 전
Alcon: A Strong Company Trading Close To Its Intrinsic Value, Buy
Alcon reported strong core operating profit (barring a one-time non-cash $402 million charge) during the quarter, up 17%. The company raised its full-year 2026 profit forecast for the second consecutive quarter. My DCF valuation states the stock is undervalued by 5.52%. I rate ALC a buy.
Alcon: A Strong Company Trading Close To Its Intrinsic Value, Buy
긍정적
Barrons
2개월 전
Bill Ackman Moves Stocks. These 5 Prove It.
Netflix, Visa and other stocks rose on the news that Bill Ackman was investing in them. The billionaire focuses on buying what he views as high-quality growth companies.
Bill Ackman Moves Stocks. These 5 Prove It.
긍정적
Market Watch
2개월 전
Bill Ackman once exited Netflix stake in a huff. Why he's buying the streaming giant again as well as these five stocks.
Netflix is once again an apple in Bill Ackman's eye, as the streamer was among six stocks Pershing Square added in the last six months.
Bill Ackman once exited Netflix stake in a huff. Why he's buying the streaming giant again as well as these five stocks.
중립
Seeking Alpha
2개월 전
Alcon Inc. (ALC) Q2 2026 Earnings Call Transcript
Alcon Inc. (ALC) Q2 2026 Earnings Call Transcript
Alcon Inc. (ALC) Q2 2026 Earnings Call Transcript
긍정적
Zacks Investment Research
2개월 전
Alcon's Q2 Earnings and Revenues Surpass Estimates, Stock Climbs
ALC's Q2 earnings and sales beat estimates as equipment and ocular health gains lift results, while the company raises its 2026 EPS outlook.
Alcon's Q2 Earnings and Revenues Surpass Estimates, Stock Climbs
Lightweight Charts™를 사용해 가격 차트를 구현했어요.